The Acute Unwanted Effects of Beta2 Receptor Agonist Therapy

Chronic elevation of plasma fibroblast growth factor 19 in long‐term farnesoid X receptor agonist therapy, a happy marriage or cause for oncological concern?

Hepatology ◽

10.1002/hep.29511 ◽

2017 ◽

Vol 67 (2) ◽

pp. 782-784 ◽

Cited By ~ 1

Author(s):

Frank G. Schaap ◽

Peter L.M. Jansen ◽

Steven W.M. Olde Damink

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Receptor Agonist ◽

Farnesoid X Receptor ◽

Fibroblast Growth ◽

Agonist Therapy ◽

Happy Marriage ◽

Fibroblast Growth Factor 19

Get full-text (via PubEx)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes

Diabetes Metabolic Syndrome and Obesity Targets and Therapy ◽

10.2147/dmso.s48837 ◽

2013 ◽

pp. 435 ◽

Cited By ~ 6

Author(s):

Mark Stolar ◽

Steve Chen ◽

Michael Grimm

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Extended Release ◽

Agonist Therapy

Get full-text (via PubEx)

Short Term Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Does Not Influence Hepatic De Novo Lipogenesis in Polycystic Ovary Syndrome

The FASEB Journal ◽

10.1096/fasebj.2021.35.s1.01661 ◽

2021 ◽

Vol 35 (S1) ◽

Author(s):

Jacob Stuppy ◽

Cameron Severn ◽

Elizabeth Parks ◽

Robert Wolfe ◽

Anne‐Marie Carreau ◽

...

Keyword(s):

Polycystic Ovary Syndrome ◽

Receptor Agonist ◽

De Novo ◽

Polycystic Ovary ◽

De Novo Lipogenesis ◽

Agonist Therapy ◽

Short Term ◽

Ovary Syndrome ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Get full-text (via PubEx)

The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2013.12.041 ◽

2014 ◽

Vol 103 (3) ◽

pp. e37-e39 ◽

Cited By ~ 16

Author(s):

Lakshminarayanan Varadhan ◽

Tracy Humphreys ◽

Adrian B. Walker ◽

George I. Varughese

Keyword(s):

Diabetic Retinopathy ◽

Glycaemic Control ◽

Receptor Agonist ◽

Agonist Therapy ◽

The Impact ◽

Improved Glycaemic Control

Get full-text (via PubEx)

Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany

PLoS ONE ◽

10.1371/journal.pone.0152281 ◽

2016 ◽

Vol 11 (3) ◽

pp. e0152281 ◽

Cited By ~ 4

Author(s):

Qing Qiao ◽

Susan Grandy ◽

Josh Hiller ◽

Karel Kostev

Keyword(s):

Type 2 Diabetes ◽

Primary Care ◽

Receptor Agonist ◽

Agonist Therapy ◽

Diabetes Patients

Get full-text (via PubEx)

??-adrenergic receptor agonist therapy for asthma is associated with an increased risk of cardiac events,

Reactions Weekly ◽

10.2165/00128415-200811990-00005 ◽

2008 ◽

Vol &NA; (1199) ◽

pp. 3

Author(s):

&NA;

Keyword(s):

Adrenergic Receptor ◽

Receptor Agonist ◽

Cardiac Events ◽

Agonist Therapy ◽

Increased Risk ◽

Adrenergic Receptor Agonist

Get full-text (via PubEx)

Review for "Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial"

10.1111/dom.14068/v1/review2 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Disease Duration ◽

Agonist Therapy ◽

Β Cell

Get full-text (via PubEx)

Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy

Postgraduate Medicine ◽

10.1080/00325481.2020.1798127 ◽

2020 ◽

Vol 132 (sup2) ◽

pp. 26-36 ◽

Cited By ~ 2

Author(s):

Eugene E. Wright Jr ◽

Vanita R. Aroda

Keyword(s):

Type 2 Diabetes ◽

Insulin Therapy ◽

Clinical Review ◽

Receptor Agonist ◽

Efficacy And Safety ◽

Agonist Therapy

Get full-text (via PubEx)

Intermittent Use of a Short-Course Glucagon-like Peptide-1 Receptor Agonist Therapy Limits Adverse Cardiac Remodeling via Parkin-dependent Mitochondrial Turnover

Scientific Reports ◽

10.1038/s41598-020-64924-2 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Juliana de F. Germano ◽

Chengqun Huang ◽

Jon Sin ◽

Yang Song ◽

Kyle C. Tucker ◽

...

Keyword(s):

Cardiac Remodeling ◽

Receptor Agonist ◽

Agonist Therapy ◽

Short Course ◽

Mitochondrial Turnover ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Get full-text (via PubEx)

Addition of low‐dose liraglutide to insulin therapy is useful for glycaemic control during the peri‐operative period: effect of glucagon‐like peptide‐1 receptor agonist therapy on glycaemic control in patients undergoing cardiac surgery ( GLOLIA study)

Diabetic Medicine ◽

10.1111/dme.14084 ◽

2019 ◽

Vol 36 (12) ◽

pp. 1621-1628

Author(s):

H. Makino ◽

A. Tanaka ◽

K. Asakura ◽

R. Koezuka ◽

M. Tochiya ◽

...

Keyword(s):

Cardiac Surgery ◽

Glycaemic Control ◽

Insulin Therapy ◽

Receptor Agonist ◽

Low Dose ◽

Period Effect ◽

Agonist Therapy ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Get full-text (via PubEx)